Allergan

Allergan, Editas Medicine partner on CRISPR genome editing medicines for eye diseases

Wednesday, March 15, 2017

Allergan, a global pharmaceutical company, and Editas Medicine, a genome editing company, have announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and development alliance under which Allergan will receive exclusive access and the option to license up to five of Editas Medicine’s genome-editing ocular programs, including its lead program for Leber Congenital Amaurosis (LCA10), which is currently in preclinical development.

[Read More]

Align Biopharma launched as industry standards group

Monday, January 30, 2017

Six of the top 25 largest global pharmaceutical companies announced the formation of Align Biopharma, a new group dedicated to setting technology standards that will make it faster and easier for healthcare professionals (HCPs) to connect with the life sciences industry. Founding members, with input from across the industry, will develop open standards and solutions for companies to streamline how HCPs get the drug and treatment information they need to deliver improved care to patients.

[Read More]

Allergan to acquire Tobira Therapeutics for $1.7B

Wednesday, September 21, 2016

Allergan, a global pharmaceutical company, and Tobira Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, have entered into a definitive agreement under which Allergan will acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to $1.695 billion.

[Read More]

Allergan to acquire Vitae Pharmaceuticals for $639M

Thursday, September 15, 2016

Allergan, a global pharmaceutical company, and Vitae Pharmaceuticals, a clinical-stage biotechnology company, have entered into a definitive agreement under which Allergan will acquire Vitae for $21.00 per share, in cash, for a total transaction value of approximately $639 million. The Boards of Directors of both companies have unanimously approved the transaction.

[Read More]

Allergan to expand in New Jersey, to create 300 jobs

Tuesday, August 16, 2016

The Board of the New Jersey Economic Development Authority (EDA) has approved Grow New Jersey (Grow NJ) tax credits to encourage the global pharmaceutical company Allergan, the U.S. subsidiary of Ireland-based Allergan, to remain in New Jersey and combine four existing company locations into a 431,495-square-foot facility in Madison. 

[Read More]

Allergan acquires Topokine Therapeutics for fat reduction development program

Monday, April 25, 2016

Allergan, a global pharmaceutical company, has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction. Allergan acquired Topokine Therapeutics for an upfront payment of $85 million and success-based development and sales milestones for XAF5, a first-in-class topical agent in late-stage development for the treatment of steatoblepharon, also known as undereye bags.

[Read More]